Prevalence and Subjective Impairment of Quality of Life (QoL) Due to Dermatologic Diseases in Internal Medicine Patients

This study has been completed.
Sponsor:
Information provided by:
University of Zurich
ClinicalTrials.gov Identifier:
NCT01044043
First received: January 6, 2010
Last updated: January 10, 2011
Last verified: January 2011
  Purpose

This is a 3 months single centre clinical patient-oriented study to evaluate the prevalence and impairment in QOL of dermatologic diseases in patients hospitalised in internal medicine.

Up to 200 patients hospitalised at the division of internal medicine for any reason are going to be offered participation by a patient information form given to patients at the time of admission, as well as oral information about the study. Written informed consent will be obtained by the investigators after patients have had adequate time to consider their participation in the study.

Participating patients will be examined clinically for dermatologic pathologies at a single visit. In the case of signs of dermatologic disease, investigators are going to recommend further diagnostic procedures to the physician in charge and/or the referring physician, depending on the urgency of the suspected diagnosis. This procedure is meant to avoid giving referring physicians the impression that active patient acquisition for the department of Dermatology is an aim of this study. Diagnostic procedures that are performed upon suspicion of a specific dermatologic disease at the Division of Internal Medicine are going to be performed during the hospitalisation period. All other diagnostic or operative procedures are going to be advised to the referring physician.

Study participants are going to be interviewed by the investigators about impairment in QOL of their illnesses. Two separate questionnaires are going to be filled in by each participant. For measurement of general QOL, the widely used SF-12 questionnaire (8 questions) is going to be used. To measure specific impairment in QOL by dermatologic disease, participants are going to be asked to fill in the DLQI (Dermatology life quality index, 10 questions). Photographic documentation of specific identified lesions will be made and pictures stored exclusively in the secured electronic patient file (KISIM). Medication and all identified diseases will be noted. All diagnostically useful information is going to be recorded in the patient file and transmitted to the referring physician in the discharge letter.


Condition Intervention
Dermatologic Disease of Inpatients in Internal Medicine
Procedure: clinical examination and quality of life questionnaire

Study Type: Observational
Study Design: Time Perspective: Prospective

Resource links provided by NLM:


Further study details as provided by University of Zurich:

Estimated Enrollment: 200
Study Start Date: November 2009
Study Completion Date: December 2010
Primary Completion Date: January 2010 (Final data collection date for primary outcome measure)
Intervention Details:
    Procedure: clinical examination and quality of life questionnaire
    clinical examination and quality of life questionnaire
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Prevalance and subjective inpairment of quality of life due to dermatologic deseases in internal medicine patients

Criteria

Inclusion criteria: Patients will be eligible for enrolment if they fulfil the following criteria:

  1. Male or female patients, age ? 18 years of age and
  2. Hospitalised at the Division of Internal Medicine, University Hospital Zurich
  3. Patients must be able to give written informed consent before any trial-specific procedures are performed (see Section 12.2).

Exclusion criteria: Patients will be excluded from the study if they fulfill any of the following criteria:

  1. Ability to communicate orally severely impaired due to any reason, namely illness or inability to speak German.
  2. Terminal patients or other patients where participation in a visit with oral and physical examination would represent an unreasonable exertion.
  3. Pregnant women
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01044043

Locations
Switzerland
Zurich, Switzerland
Sponsors and Collaborators
University of Zurich
Investigators
Study Director: 01 Studienregister MasterAdmins UniversitaetsSpital Zuerich
  More Information

No publications provided

Responsible Party: University Hospital Zurich, Edouard Battegay, Switzerland: University of Zurich
ClinicalTrials.gov Identifier: NCT01044043     History of Changes
Other Study ID Numbers: PREV_DERM_INTMED
Study First Received: January 6, 2010
Last Updated: January 10, 2011
Health Authority: Switzerland: UZurich

Additional relevant MeSH terms:
Skin Diseases

ClinicalTrials.gov processed this record on July 20, 2014